Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenues:
Clinical treatment programs	$ 49	$ 36	$ 121	$ 78
Total Revenues	49	36	121	78
Costs and Expenses:
Production/cost of goods sold	208	204	488	397
Research and development	1,736	1,624	3,401	3,264
General and administrative	1,738	1,456	3,612	3,255
Total costs and expenses	3,682	3,284	7,501	6,916
Operating loss	(3,633)	(3,248)	(7,380)	(6,838)
Interest expense	(1)	(6)	(12)	(12)
Interest and other income	247	317	520	474
Funds received from sale of income tax net operating losses	0	0	1,328	2,272
Redeemable warrants valuation adjustment	387	643	236	944
Net loss	(3,000)	(2,294)	(5,308)	(3,160)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	187	(154)	584	(141)
Realized (loss) on marketable securities	(21)	(941)	(37)	(495)
Less: Premium amortization	48	0	108	0
Net comprehensive loss	$ (2,786)	$ (3,389)	$ (4,653)	$ (3,796)
Basic and diluted loss per share	$ (0.02)	$ (0.02)	$ (0.04)	$ (0.02)
Weighted average shares outstanding basic and diluted	135,974,216	135,375,375	135,880,841	135,320,311